Ling Yui Holdings Limited: Detailed Update on Offer Closure, Clarification, and Public Float Status
Key Points for Investors
- Completion of Unconditional Mandatory Cash Offer: The unconditional mandatory cash offer by Hapbiotech Investment Holding Limited (the “Offeror”) for all issued shares in Ling Yui Holdings Limited (the “Company”), except those already owned or agreed to be acquired by the Offeror and its concert parties, has officially closed.
- Clarification of Public Float Requirement: A correction was issued regarding the Listing Rules governing the minimum public float. The Joint Announcement previously cited “Rule 8.08(1)(a)” for the 25% public float requirement, but the accurate rule is “Rule 13.32B(1)”. This is important for compliance and investor confidence.
- Board and Director Details: The announcement confirms the composition of both the Company’s Board and the Offeror’s directorate, giving clarity on leadership and governance as the transaction concludes.
- Responsibility Statement: Both Boards have reiterated their responsibility for the accuracy of this announcement, which is critical for investor trust.
- Availability of Information: This announcement will remain available on the Stock Exchange and Company websites for at least seven days, ensuring transparency to all stakeholders.
Important Information for Shareholders
- Outcome of the Offer: The offer has closed, meaning shareholders who tendered their shares will receive settlement as outlined. No further opportunity exists to participate in the offer.
- Public Float Compliance: The correction to the Listing Rule ensures that the Company remains compliant with the Hong Kong Stock Exchange’s requirement that at least 25% of shares remain in public hands. If public float falls below this threshold, it could affect trading liquidity and possibly trigger regulatory actions.
- Potential Price Sensitivity: The completion of the mandatory cash offer and clarification on public float could have an impact on share price, as they affect both ownership concentration and regulatory compliance. Investors should monitor trading activity and regulatory disclosures closely.
- Governance Update: The precise listing of directors involved provides insight into the post-offer leadership. Leadership changes or confirmations can influence investor sentiment.
Detailed Announcement Summary
The joint announcement by Hapbiotech Investment Holding Limited and Ling Yui Holdings Limited details the closure of the unconditional mandatory cash offer for the Company’s shares. The offer was managed by Red Sun Capital Limited, acting on behalf of the Offeror. The offer targeted all shares not already owned or agreed to be acquired by the Offeror and its concert parties.
A clarification was made regarding the Company’s minimum public float requirement under the Hong Kong Stock Exchange Listing Rules. The correct rule cited is “Rule 13.32B(1)”, which mandates that at least 25% of the Company’s issued shares must be held by the public. This compliance is crucial for maintaining listing status and trading liquidity.
Leadership details were provided: Hapbiotech Investment Holding Limited’s sole director is Dr. Xu Mingyan. Ling Yui Holdings Limited’s Board comprises Chairman and Executive Director Ling Chi Fai, other executive directors, a non-executive director, and several independent non-executive directors. The directors of HI include Dr. Xu Mingyan, Dr. Chen Shifu, Ms. Wen Yuan, Ms. Liu Ying, Mr. Zhang Hao, and Ms. Li Lining.
Both Boards have jointly and severally accepted responsibility for the accuracy and completeness of the information contained in the announcement, confirming it is the result of due and careful consideration.
For transparency, this announcement will remain publicly available on the Stock Exchange and Company websites for at least seven days, allowing shareholders and investors to review the full details.
Potential Impact on Share Price
- Completion of the cash offer and clarification on public float rules may influence market sentiment, trading volumes, and liquidity.
- Any breach or uncertainty regarding public float requirements can lead to regulatory actions or trading suspensions, impacting share value.
- Changes or confirmations in Board composition may affect investor confidence and perception of future corporate governance.
Disclaimer
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions based on this announcement. The information provided is based on the official joint announcement and may be subject to further updates or changes.
嶺睿控股有限公司：收購完成、澄清及公開持股詳情報導
投資者需注意的重點
- 無條件強制現金收購已完成： Hapbiotech Investment Holding Limited（「要約人」）對嶺睿控股有限公司（「公司」）全部已發行股份（除要約人及一致行動人士已擁有或已同意收購者）之無條件強制現金收購已正式結束。
- 公開持股規則澄清： 聯合公告更正了有關公開持股最低要求的上市規則，正確規則為「規則13.32B(1)」，要求至少25%股份需由公眾持有，對於合規及投資者信心至關重要。
- 董事會及管理層詳情： 公告確認公司及要約人董事會成員，讓投資者清楚交易後的領導層及公司治理。
- 責任聲明： 兩董事會重申對公告準確性的責任，對投資者信任至關重要。
- 信息公開： 公告將於港交所及公司網站上公佈至少七天，保持資訊透明。
股東需知的重要信息
- 要約結果： 要約已結束，已提交股份的股東將按公告安排獲得結算，後續不再有參與要約機會。
- 公開持股合規： 公開持股規則更正確保公司符合港交所25%公開持股要求。若低於此門檻，或影響流動性及觸發監管行動。
- 潛在價格敏感： 收購完成及公開持股澄清可能影響股價，投資者應密切留意交易動態及監管公告。
- 公司治理更新： 董事會成員詳情有助投資者掌握收購後公司領導層變動，可能影響市場信心。
公告詳情摘要
Hapbiotech Investment Holding Limited與嶺睿控股有限公司聯合公告，詳細說明無條件強制現金收購的結束。該收購由紅日資本有限公司代表要約人進行，目標為所有未由要約人及一致行動人士持有或同意收購的股份。
公告澄清公司公開持股最低要求的上市規則為「規則13.32B(1)」，需至少25%股份由公眾持有，這對於維持上市及交易流動性至關重要。
管理層詳情：要約人唯一董事為徐明艷博士；嶺睿控股有限公司董事會有主席兼執行董事嶺志輝及多位執行、非執行及獨立非執行董事；HI的董事包括徐明艷博士、陳世福博士、文媛女士、劉穎女士、張浩先生及李麗寧女士。
兩董事會共同及分別承擔公告資訊準確性的責任，並確認經過充分考慮。
公告將於港交所及公司網站公佈至少七天，方便股東及投資者查閱詳情。
對股價的潛在影響
- 現金收購完成及公開持股規則澄清，可能影響市場情緒、交易量及流動性。
- 公開持股不足或規則不明，可能導致監管行動或停牌，影響股價。
- 董事會成員變動或確認，可能影響投資者信心及公司治理評價。
免責聲明
免責聲明： 本文章僅作資訊參考，不構成投資建議。投資者應自行進行盡職調查，並諮詢專業顧問後才根據本公告作出任何投資決策。本文資訊來自官方聯合公告，可能會有後續更新或變動。
